• GERD:
    • Symptomatic non-erosive:
      • Adult: PO/NG 20mg OD *4-8 weeks
      • 1-16 years (>20 kg, Off-label): PO/NG 20mg OD *4-8 weeks OR initially 1mg/kg/day divided OD/BD, then 0.2-3.5mg/kg/day divided OD/BD
    • Short-term treatment in erosive esophagitis:
      • Adult: PO/NG 20mg OD *4-12 weeks
      • 1-16 years (>20 kg, Off-label): PO/NG 20mg OD OR initially 1mg/kg/day divided OD/BD, then 0.2-3.5mg/kg/day divided OD/BD
    • Maintenance treatment in erosive esophagitis:
      • Adult: PO/NG 20mg OD
      • 1-16 years (>20 kg, Off-label): PO/NG 20mg OD OR initially 1mg/kg/day divided OD/BD, then 0.2-3.5mg/kg/day divided OD/BD
  • Duodenal ulcer:
    • PO/NG 20-40mg OD *4-8 weeks
  • Gastric ulcer:
    • PO/NG 40mg OD *4-8 weeks
  • Risk reduction of upper GI bleeding in critically ill patients:
    • NG 40mg initially then 40mg *1, 6-8 hours later; then 40mg OD *14/7
    • Suspend tube feeding 3 hours before and 1 hour after
  • Heartburn:
    • PO 20mg OD *14/7
  • Prophylaxis of NSAID-associated gastric ulcer (Off-label):
    • PO/NG 20-40mg OD
  • Hypersecretory conditions(Off-label):
    • Initially PO/NG 60mg OD
    • Dose is individualized
    • Divide doses >80 mg/day
  • Powder:
    • 20mg/1680mg
    • 40mg/1680mg
  • To be given 1 hour before meals on an empty stomach
  • Do not mix with liquids or foods other than water
  • Put the powder in water (about 5-10mL) and drink immediately
  • For NG/OG tube administration, add 20mL of water to a catheter tipped syringe and then add the contents of a packet

Omeprazole: PPI; it inhibits gastric parietal cell hydrogen-potassium ATPase resulting in suppression of basal and stimulated acid secretion

Sodium bicarbonate: Antacid; it increases gastric pH, enhancing absorption of omeprazole

  • Headache
  • Abdominal pain
  • Diarrhea
  • URI symptoms (peds patients)
  • Hypertension (critically ill patients)
  • Fever (critically ill patients)
  • Thrombocytopenia (critically ill patients)
  • Oral candidiasis (critically ill patients)
  • Hypotension (critically ill patients)
  • Hyperpyrexia (critically ill patients)
  • Atrial fibrillation (critically ill patients)
  • Hypophosphatemia (critically ill patients)
  • Vitamin B12 deficiency (long-term use)
  • Fundic gland polyps (long-term use)
  • Hypersensitivity to class/components
  • Bartter syndrome
  • Alkalosis
  • Hypokalemia
  • Hypocalcemia
  • Asian patients (erosive esophagitis maintenance treatment use in patients with unknown CYP2C19 genotype)
  • Poor CYP2C19 metabolizers (erosive esophagitis maintenance treatment use)
  • Hepatic impairment (erosive esophagitis maintenance treatment use)
  • Erlotinib
  • Mavacamten
  • Nelfinavir
  • Rilpivirine

                          Drug Status

Availability OTC
Pregnancy Not recommended
Breastfeeding Use with caution
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Aprazole Plus 20mg/1680mg Sachet 20’s Ajanta Pharma Harley’s Ltd
Risek Insta 20mg/1680mg Sachet 10’s Getz Pharma Surgipharm Ltd
Risek Insta 40mg/1680mg Sachet 10’s Getz Pharma Surgipharm Ltd